ENSC (Ensysce Biosciences) Beneish M-Score : 0.00 (As of Dec. 12, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Ensysce Biosciences's Beneish M-Score or its related term are showing as below:

During the past 4 years, the highest Beneish M-Score of Ensysce Biosciences was 0.00. The lowest was 0.00. And the median was 0.00.

Ensysce Biosciences Beneish M-Score Historical Data

The historical data trend for Ensysce Biosciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensysce Biosciences Beneish M-Score Chart

Ensysce Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Ensysce Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beneish M-Score	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Ensysce Biosciences's Beneish M-Score

For the Biotechnology subindustry, Ensysce Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ensysce Biosciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ensysce Biosciences's Beneish M-Score falls into.

Ensysce Biosciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ensysce Biosciences for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Sep24) TTM:

Last Year (Sep23) TTM:

Total Receivables was $1.78 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $9.09 Mil.
Total Assets was $9.39 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $5.08 Mil.
Total Current Liabilities was $2.80 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was 0.662 + -1.968 + -3.116 + -3.503 = $-7.93 Mil.
Non Operating Income was 0.021 + 0.015 + -0.026 + -0.004 = $0.01 Mil.
Cash Flow from Operations was -1.02 + -2.31 + -3.408 + -1.802 = $-8.54 Mil.

Total Receivables was $0.11 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $2.76 Mil.
Total Assets was $3.22 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $5.12 Mil.
Total Current Liabilities was $2.03 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(1.783 / 0)	/	(0.108 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (9.091 + 0) / 9.385)	/	(1 - (2.758 + 0) / 3.219)
	=	0.031327	/	0.143212
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0 / (0 + 0))	/	(0 / (0 + 0))
	=		/
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(5.081 / 0)	/	(5.116 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0 + 2.802) / 9.385)	/	((0 + 2.031) / 3.219)
	=	0.298562	/	0.630941
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-7.925 - 0.006	-	-8.54)	/	9.385
	=	0.064891

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ensysce Biosciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Ensysce Biosciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensysce Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037

Website

https://www.ensysce.com

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Executives

Bob G Gower	director	402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick	director, officer: Chief Executive Officer	110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman	officer: Chief Medical Officer	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch	director	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano	officer: Chief Development Officer	7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett	officer: Chief Commercial Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt	officer: Chief Medical Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey	officer: Chief Financial Officer	4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang	director, 10 percent owner	C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard	officer: Chief Operating Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright	officer: Chief Business Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin	director	11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037